Sobi enters partnership with Tigenix for the commercialisation of ChondroCelect

        Print
| Source: Swedish Orphan Biovitrum AB
Swedish Orphan Biovitrum AB (publ) (Sobi) announced today that the company has
acquired the licencing rights to market and distribute ChondroCelect, a cell-
based medicinal product for the repair of cartilage defects of the knee, from
TiGenix NV (Euronext Brussels: TIG).

ChondroCelect was the first cell-based product to be approved in Europe. It is
currently available for patients and reimbursed in Belgium, the Netherlands and
Spain. Sobi will continue to market and distribute the product where it is
currently available and will work to expand the product's availability to
patients in a much wider area, including the rest of the European Union, Norway,
Russia, Switzerland, Turkey, and the countries in the Middle East and North
Africa.

"We are delighted to reach this agreement with Sobi", said Eduardo Bravo, CEO of
Tigenix. "With their experience of marketing and distributing specialty products
Sobi has the ability to bring ChondroCelect to a far greater number of patients
in many more countries."

"ChondroCelect is an exciting therapy, and we are proud to expand our offering
to orthopaedic patients," said Anders Edvell, MD, PhD, and Vice President Sobi
Partner Products. "This partnership is an excellent fit with Partner Products'
strategy for achieving sustainable patient access to new and innovative
treatments with a pan-European scope."

---

About ChondroCelect

ChondroCelect, indicated for cartilage repair in the knee, is a cell-based
medicinal product for use in autologous chondrocyte implantation in which cells
are taken from the patient's own knee, multiplied to reach a large quantity, and
then re-implanted at the site of the defect.

About Sobi

Sobi is an international specialty healthcare company dedicated to rare
diseases. Our mission is to develop and deliver innovative therapies and
services to improve the lives of patients. The product portfolio is primarily
focused on Inflammation and Genetic diseases, with three late stage biological
development projects within Haemophilia and Neonatology. We also market a
portfolio of specialty and rare disease products for partner companies. Sobi is
a pioneer in biotechnology with world-class capabilities in protein biochemistry
and biologics manufacturing. In 2013, Sobi had total revenues of SEK 2.2 billion
(€253 M) and about 550 employees. The share (STO: SOBI) is listed on NASDAQ OMX
Stockholm. More information is available at www.sobi.com.

About Sobi Partner Products

Sobi Partner Products (SPP) is a business unit within Sobi which offers a unique
commercial platform for partners with niche and specialty products. SPP provides
extensive knowledge and local experience through our direct presence across EU,
Eastern Europe, Russia, Middle East and North Africa. We apply an integrated
commercial, medical, and market access approach to products which address
important unmet needs, spanning from named patient use (NPU) programs, through
to reimbursement and full commercialization, primarily in the Centre of
Expertise setting.


For more information please contact

Media relations
Oskar Bosson, Head of Communications
T: +46 70 410 71 80
oskar.bosson@sobi.com

Investor relations
Jörgen Winroth, Vice President, Head of Investor Relations
T: +1 347-224-0819, +1 212-579-0506, +46 8 697 2135
jorgen.winroth@sobi.com




[HUG#1774000]